Ipsen had a robust presence at the 12th World Congress for Neurorehabilitation (WCNR) in Vienna, Austria and virtually, from 14-17 December 2022, further demonstrating the company’s long-standing partnership with the World Federation for Neurorehabilitation (WFNR) and ongoing commitment to neuroscience. In addition to showcasing the company’s latest neuroscience clinical data, Ipsen hosted a satellite symposium…
Lecanemab: Clarity AD clinical study results
Results from Eisai’s large global Phase 3 confirmatory Clarity AD clinical study of lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain, were presented at the…
Zilucoplan for the treatment of generalised myasthenia gravis in adult patients
FDA acceptance of new drug application and EMA MAA validation On 14th November 2022, UCB announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its investigational treatment, zilucoplan. Zilucoplan is a subcutaneous (SC), self-administered peptide inhibitor of complement component 5 (C5 inhibitor) for the treatment…
Upstaza™ gene therapy granted marketing authorisation for AADC deficiency by MHRA
PTC Therapeutics, Inc. announced on 17th November that Upstaza™ (eladocagene exuparvovec) was granted authorisation by the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain. Upstaza is the first and only approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency and the first marketed gene therapy directly infused into the brain. It is approved for patients 18…
First autopsy-confirmed results for identifying Alzheimer’s in presence of other co-morbid pathologies using DISCERN test
SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialisation of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce the publication of “Morphometric imaging biomarker identifies Alzheimer’s disease even among mixed dementia patients” in Scientific Reports. Up until now, there have been no autopsy-validated tests shown to accurately identify AD…
Tecfidera lowers risk of first MS symptoms in RIS
Treatment with Tecfidera (dimethyl fumarate) significantly reduces the risk of experiencing the first multiple sclerosis (MS) symptoms in adults with radiologically isolated syndrome (RIS), according to data from a Phase 4 clinical trial which may lead to changes in practice. RIS is a condition in which patients have MS-like lesions on MRI scans, but lack typical symptoms of the disease. This…
EMD Serono highlights new data for Evobrutinib
First BTKi to demonstrate sustained clinical benefit for people with RMS through three and a half years of treatment Phase II clinical trial data of evobrutinib demonstrated low disease activity and stable EDSS, with NfL levels, a marker of neuronal injury, remaining low in people with RMS after three and a half years of therapy…
Laser Therapy for Epilepsy now available on the NHS
NHS England has accepted the recommendation of the Clinical Priorities Advisory Group to roll out LITT (laser interstitial thermal therapy) on the NHS. LITT is a laser treatment for epilepsy offering a less invasive alternative to conventional neurosurgery. It is a stereotactic procedure with the potential for seizure reduction results similar to those of open resection, with…
AssistiveTech in the UK
Ecosystem Overview and ATLAS Advocacy Launched in House of Lords AssistiveTech poised for rapid growth in the UK, tackling key socio-economic challenges. The official launch event and key findings of the new ‘AssistiveTech in the UK’ interactive report, developed by ATLAS (Assistive Technology, Longevity and Ageing Society) with the support of Aging Analytics Agency and…
